Investigators argue that abandoning a decade of research just because the only person who ever took the treatment suffered a massive medical emergency represents a rush to judgment.
After a three-year pause, the FDA has cleared investigators to resume a decade-in-the-making sickle cell gene therapy trial, as experts caution that the catastrophic medical emergency suffered by the trial's first and only participant does not definitively prove the treatment is a guaranteed disaster.
The highly anticipated therapeutic was abruptly halted in 2021 when patient zero experienced a severe adverse event immediately upon receiving the initial dose. However, researchers now argue that terminating a study based on an n of 1 fails to account for natural biological variance, noting that a single devastating outcome is simply too small a sample size from which to draw any meaningful conclusions about whether the therapy is fundamentally toxic.
While the initial administration of the compound was strongly correlated with a life-threatening decline in the patient's vital functions, we must remember the difference between association and causation.
A recent peer-reviewed retrospective on the trial's early suspension highlighted the methodological flaws of abandoning the genetic editing technique entirely. Study authors pointed out that the first patient's sudden, massive organ distress could simply be a confounding variable, and that shutting down the clinic before dosing a second or third subject deprives the scientific community of a complete dataset.
Medical ethicists advise taking the upcoming phase two resumption with a requisite dose of caution, noting that even if the next participant manages to survive the injection, more data will be required to rule out a placebo effect.